We are live on ! Find out more
LPCN icon

Lipocine
LPCN

29 hedge funds and large institutions have $3.73M invested in Lipocine in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,271% more call options, than puts

Call options by funds: $96K | Put options by funds: $7K

1% more capital invested

Capital invested by funds: $3.7M → $3.73M (+$27.9K)

0.04% less ownership

Funds ownership: 0.79% → 0.75% (-0.04%)

3% less funds holding

Funds holding: 30 → 29 (-1)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
29
Holders Change
-1
Holders Change %
-3.33%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
9
Reduced
11
Closed
1
Calls
$96K
Puts
$7K
Net Calls
+$89K
Net Calls Change
+$110K

Top Buyers

1
Ameriprise
Ameriprise
Minnesota
+$120K
2
JP Morgan Chase
JP Morgan Chase
New York
+$81.9K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$50.6K
4
Renaissance Technologies
Renaissance Technologies
New York
+$42.4K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$41.7K

Top Sellers

1
JGC
J. Goldman & Co
New York
-$310K
2
Morgan Stanley
Morgan Stanley
New York
-$127K
3
Group One Trading
Group One Trading
Illinois
-$63.3K
4
Citadel Advisors
Citadel Advisors
Florida
-$23.7K
5
ARTA
A.R.T. Advisors
New York
-$10.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.03M +$50.6K +2,059 +5%
JGC
2
J. Goldman & Co
New York
$691K -$310K -12,609 -30%
BlackRock
3
BlackRock
New York
$416K +$2.07K +84 +0.5%
Ameriprise
4
Ameriprise
Minnesota
$337K +$120K +4,882 +51%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$205K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$187K +$42.4K +1,724 +28%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$144K – – –
JP Morgan Chase
8
JP Morgan Chase
New York
$132K +$81.9K +3,329 +146%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$83K -$7.03K -286 -7%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$74K +$41.7K +1,695 +116%
Northern Trust
11
Northern Trust
Illinois
$70K – – –
KCM
12
Knoll Capital Management
Florida
$69K – – –
California Public Employees Retirement System
13
California Public Employees Retirement System
California
$63K – – –
Barclays
14
Barclays
United Kingdom
$44K – – –
Group One Trading
15
Group One Trading
Illinois
$33K -$63.3K -2,575 -65%
VF
16
Virtu Financial
New York
$28K -$7.25K -295 -20%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$20K – – –
State Street
18
State Street
Massachusetts
$18K -$1.3K -53 -7%
CG
19
Cutler Group
California
$17K – – –
ARTA
20
A.R.T. Advisors
New York
$16K -$10.8K -440 -39%
LTFS
21
Ladenburg Thalmann Financial Services
Florida
$11K -$2.46K -100 -18%
Deutsche Bank
22
Deutsche Bank
Germany
$11K -$271 -11 -2%
UBS Group
23
UBS Group
Switzerland
$10K +$6.22K +253 +169%
MAM
24
Meeder Asset Management
Ohio
$8K +$5.21K +212 +151%
Federated Hermes
25
Federated Hermes
Pennsylvania
$4K -$3.05K -124 -40%
1
2

LPCN Hedge Fund Activity: Q3 2018 in Review

29 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2018, worth a combined $3.73M — up 0.75% from $3.7M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of LPCN and 0 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 9 added.

The largest buyer was Ameriprise, adding an estimated $120K. The largest seller was J. Goldman & Co, cutting an estimated $310K.

  • 29 institutional investors held Lipocine (LPCN) as of Q3 2018, down from 30 in Q2 2018.
  • Funds reported $3.73M of Lipocine stock for Q3 2018, up 0.75% quarter-over-quarter.
  • 0 funds opened new Lipocine positions in Q3 2018 and 1 closed out, a net change of -1 holder.
  • The largest Lipocine buyer in Q3 2018 was Ameriprise, an estimated $120K added.
  • The largest Lipocine seller in Q3 2018 was J. Goldman & Co, an estimated $310K sold.

Based on aggregated 13F filings for Q3 2018.